Deals23 Dec 2025, 05:47 pm
Biocon Limited signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
AI Summary
Biocon Limited, an innovation-led global biopharmaceutical company, has signed an out-licensing agreement with Ajanta Pharma Ltd to market its drug product, Semaglutide, used to improve glycemic control in adults with type-2 diabetes. Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia. Ajanta is a leading Indian pharmaceutical company with a strong presence in these markets. This partnership is a strategic step in expanding Biocon’s GLP-1 portfolio globally and maximizing the value of its scientific investments in complex peptide development.
Key Highlights
- Biocon Limited has signed an out-licensing agreement with Ajanta Pharma Ltd to market Semaglutide in 26 countries.
- Semaglutide is used to improve glycemic control in adults with type-2 diabetes.
- Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia.
- Ajanta is a leading Indian pharmaceutical company with a strong presence in these markets.
- This partnership is a strategic step in expanding Biocon’s GLP-1 portfolio globally and maximizing the value of its scientific investments in complex peptide development.